Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; iron oxide yellow; povidone; magnesium stearate - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 500 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; iron oxide yellow; povidone - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - olsalazine sodium, quantity: 500 mg - tablet, uncoated - excipient ingredients: povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; ethanol - indications: treatment of ulcerative colitis in patients intolerant of sulphasalazine.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; sunset yellow fcf - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 750 mg - tablet, modified release - excipient ingredients: sunset yellow fcf; magnesium stearate; hypromellose - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis)

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory

Australien - engelska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; purified water; sunset yellow fcf; magnesium stearate - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.

Malta - engelska - Medicines Authority

atnahs pharma netherlands b.v. copenhagen towers Ørestads boulevard 108, 5.tv dk-2300 københavn s , denmark - lisinopril dihydrate - tablet - lisinopril dihydrate 5 mg - agents acting on the renin-angiotensin system